Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-DOTAGA-IAB56
- Development stage
- Preclinical
- Lead developer
- ImaginAb
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-DOTAGA-IAB56 is a radiopharmaceutical therapy (RPT) agent consisting of a minibody (IAB56) conjugated to the chelator DOTAGA and radiolabeled with the beta-emitting isotope Lutetium-177 (177Lu). The minibody is an 80 kDa antibody fragment composed of two scFv antigen-binding domains fused to the CH3 domain of human IgG, designed for rapid blood clearance and high target affinity. It specifically targets integrin alpha-V beta-6 (αVβ6), a cell surface protein that is significantly upregulated in various carcinomas, including pancreatic ductal adenocarcinoma, while remaining largely absent in healthy adult tissues. Developed by ImaginAb, this agent aims to deliver targeted radiation to tumor cells while minimizing hematological and off-target organ exposure. Preclinical studies in pancreatic cancer xenograft models have demonstrated significant tumor growth inhibition and improved survival.
- Other names
- 177Lu-IAB56minibody 177Lu-DOTAGA-IAB56minibody177Lu-DOTAGA-IAB56minibody-177Lu-DOTAGA-IAB56
02
Targets
αVβ6 (Integrin αVβ6)
Beyond the preview
Go deeper on 177Lu-DOTAGA-IAB56.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-DOTAGA-IAB56.